Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres
- 349 Downloads
Objective The aim of this study was to assess the consumption of anti-haemophilic drugs by adults and children with severe haemophilia A or B (residual activity of FVIII or FIX ≤2%) and to quantify the average direct medical costs. Method A retrospective multicentre cost-of-illness study from the perspective of French national health insurance system. The costs include only the use of clotting factors. Main outcome measure Consumption was expressed in UI/kg/year and costs in euros/kg/year. Results From January 1, 2001 to December 31, 2002, data from 81 adults and 30 children with severe haemophilia A (n = 92) or B (n = 19) and included in the “SNH” were collected and analysed. A coagulation factor inhibitor was present in 10 patients (9%). Four of them were high responders. Mean age and body weight were respectively 28 ± 17 years and 58 ± 24 kg. Except for one adult patient, all (99%) had outpatient treatment, 44 patients (40%) were hospitalized and treated by recombinant or/and plasma-derived FVIII or FIX or/and rFVIIa. Overall median annual consumption of anti-haemophilic drugs per patient was estimated at 1,333 UI/kg, with a median cost-of-illness of 1,156 euros/kg. Patients with severe haemophilia B consumed more than patients with severe haemophilia A, though not significantly (P = 0.096), with a median of 2,167 vs. 1,100 UI/kg/year and a median cost of 1,760 vs. 917 euros/kg/year (P = 0.13). Children consumed respectively more than adults (P = 0.008), with a median of 3,204 vs. 1,106 UI/kg/year and a median cost of 2,614 vs. 913 euros/kg/year (P = 0.012). The median cost for patients with an inhibitor was 3,291 euros/kg/year, approximately threefold higher than that of patients without an inhibitor (926 euros/kg/year) (P = 0.022). Conclusion It suggests a higher consumption and cost of anti-haemophilic drugs among children when compared to adults. Haemophilia B patients did not consume significantly more than haemophilia A patients, whereas the consumption and cost for patients with or without inhibitors differed significantly.
KeywordsClotting factors Cost-of-illness France Haemophilia Pharmacoeconomics
We are indebted to Bayer Laboratory and Biotech Division for logistic and organisational assistance. We also thank Ms Pamela Albert for English assistance in the correction of the manuscript.
Conflicts of interest
There is no potential conflict of interest related to the content of this manuscript.
- 3.Sultan Y. The French Hemophilia Study Group. Prevalence of inhibitors in a population of 3,435 hemophilia patients in France. Thromb Haemost 1992;67:600–2Google Scholar
- 5.Jasso-mosqueda JG, Omnès LF, Gomez E, et al. Description of the management of patients suffering from type A haemophilia [Description de la prise en charge de l’hémophilie sévère de type A par le programme de médicalisation des Systèmes d’information : intérêts et limites]. J Econ Med 2000;18:323–30Google Scholar
- 6.D’Alche-Gautier MJ, Gautier P, Stieltjes N, et al. Economic study of clotting factor therapy in haemophilia [Coût du traitement substitutif des hémophiles hospitalisés]. J Econ Med 2001;19:157–66Google Scholar